These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31304677)

  • 1. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells.
    Ray AK; Somanchi SS; Dastgheyb N; Aquino-Lopez A; Cobanoglu ZE; Geier B; Lee DA
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27783. PubMed ID: 31304677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
    Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
    Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxicity of activated natural killer cells against pediatric solid tumors.
    Cho D; Shook DR; Shimasaki N; Chang YH; Fujisaki H; Campana D
    Clin Cancer Res; 2010 Aug; 16(15):3901-9. PubMed ID: 20542985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
    Veneziani I; Brandetti E; Ognibene M; Pezzolo A; Pistoia V; Cifaldi L
    J Immunol Res; 2018; 2018():4972410. PubMed ID: 29805983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of antileukemia effects of allogeneic NK cells.
    Leung W; Iyengar R; Turner V; Lang P; Bader P; Conn P; Niethammer D; Handgretinger R
    J Immunol; 2004 Jan; 172(1):644-50. PubMed ID: 14688377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer cell crossmatch: functional analysis of inhibitory killer immunoglobulin-like receptors and their HLA ligands.
    Han M; Fallena M; Guo Y; Stastny P
    Hum Immunol; 2007 Jun; 68(6):507-13. PubMed ID: 17509450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors.
    Re F; Staudacher C; Zamai L; Vecchio V; Bregni M
    Cancer; 2006 Aug; 107(3):640-8. PubMed ID: 16804934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.
    Zhang H; Cui Y; Voong N; Sabatino M; Stroncek DF; Morisot S; Civin CI; Wayne AS; Levine BL; Mackall CL
    J Immunother; 2011 Mar; 34(2):187-95. PubMed ID: 21304401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells.
    Jarahian M; Watzl C; Issa Y; Altevogt P; Momburg F
    Int J Cancer; 2007 Jun; 120(12):2625-34. PubMed ID: 17294447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Killer immunoglobulin-like receptors and tumor immunity.
    Benson DM; Caligiuri MA
    Cancer Immunol Res; 2014 Feb; 2(2):99-104. PubMed ID: 24592397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.
    Ewen EM; Pahl JHW; Miller M; Watzl C; Cerwenka A
    Eur J Immunol; 2018 Feb; 48(2):355-365. PubMed ID: 29105756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
    Lelaidier M; Dìaz-Rodriguez Y; Cordeau M; Cordeiro P; Haddad E; Herblot S; Duval M
    Oncotarget; 2015 Oct; 6(30):29440-55. PubMed ID: 26320191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
    Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
    BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
    Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
    Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers.
    Kimpo MS; Oh B; Lee S
    Curr Oncol Rep; 2019 Sep; 21(10):93. PubMed ID: 31502008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
    Suck G; Odendahl M; Nowakowska P; Seidl C; Wels WS; Klingemann HG; Tonn T
    Cancer Immunol Immunother; 2016 Apr; 65(4):485-92. PubMed ID: 26559813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implication of Highly Cytotoxic Natural Killer Cells for Esophageal Squamous Cell Carcinoma Treatment.
    Lim KS; Mimura K; Kua LF; Shiraishi K; Kono K
    J Immunother; 2018; 41(6):261-273. PubMed ID: 29683892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.